Page 209 of 282: studies 2,081 to 2,090 of 2,815, newest first. Back to the LSD overview
July 27, 2022 Rebekah Senanayake
<p>Disruptions to the sense of self are dotted across cultures and times in rituals involving hallucinogens, sensory deprivation, trance possession, and meditation. Much of the research on the self or “ego” suggests that the self is a complicated, multi-faceted entity and that there are many aspects that hold together our ego. Yet, current measurements on ego-dissolution focus on a narrow...
Royal Society of Chemistry eBooks July 22, 2022
Tryptamine (2-(1H-indol-3-yl)ethan-1-amine) is a naturally-occurring metabolite of the amino acid tryptophan, which, in turn, is a constituent of many proteins. Although tryptamine has few significant pharmacological properties, it forms the parent nucleus of a number of hallucinogenic drugs. Some of these tryptamines are derived from plant material or animals and have been used in certain...
bioRxiv (Cold Spring Harbor Laboratory) July 13, 2022 Andrea I. Luppi, Justine Y. Hansen, Ram Adapa et al. 5 citations preprint
Abstract To understand how pharmacological interventions can exert their powerful effects on brain function, we need to understand how they engage the brain’s rich neurotransmitter landscape. Here, we bridge microscale molecular chemoarchitecture and pharmacologically-induced macroscale functional reorganisation, by relating the regional distribution of 19 neurotransmitter receptors and...
Indian Journal of Psychiatry July 1, 2022 Gokul Raj 3 citations
Sir, Psychedelic studies have reported positive results for depression and anxiety related to cancer and other life-threatening illnesses, treatment-resistant depression, and tobacco and alcohol dependence.[1] Although there are no active psychedelic research studies going on in India, there is growing interest about these substances as evident by numerous social media groups and pages with a...
Journal of Substance Abuse Treatment July 1, 2022 Patrick Köck, Katharina Froelich, Marc Walter et al. 68 citations
Iboga and its primary alkaloids, ibogaine and noribogaine, have been of interest to researchers and practitioners, mainly due to their putative efficacy in treating substance use disorders (SUDs). For many SUDs, still no effective pharmacotherapies exist. Distinct psychoactive and somatic effects of the iboga alkaloids set them apart from classic hallucinogens like LSD, mescaline, and...
Current Pain and Headache Reports June 27, 2022 Sakari Santeri Rusanen, Suchetana De, Emmanuelle A. D. Schindler et al. 12 citations
Abstract Purpose of Review The use and efficacy of various substances in the treatment of CH have been studied in several retrospective surveys. The aim of the study is to systematically review published survey studies to evaluate the reported efficacies of both established and unconventional substances in abortive and prophylactic treatment of both episodic and chronic CH, specifically...
Scientific Reports June 22, 2022 Grant Jones, Joshua Lipson, Matthew K. Nock 31 citations
Abstract Tobacco use is the single largest cause of preventable death worldwide, but none of the established treatments aimed at smoking cessation work for a majority of smokers. As such, there is an urgent need for interventions capable of reliably treating nicotine addiction. The use of classic psychedelics has been associated with lower odds of many forms of substance dependence. Here we...
Addiction Neuroscience June 22, 2022 Fúlvio Rieli Mendes, Cristiane Dos Santos Costa, Victor Distefano Wiltenburg et al. 55 citations
Substance use disorder (SUD) is a global public health concern that affects millions of people worldwide. Considering current research, addiction has been noted as the last stage of a chronic disease that may impair brain reward circuit responses and affects personal and social life. Treatments for SUD face challenges including availability and limited pharmacological response, often resulting...
Neuropsychopharmacology June 21, 2022 Gitte M. Knudsen 56 citations
The serotonergic classical psychedelics include compounds that primarily activate the brain's serotonin 2 A receptor (5-HT2AR), such as LSD, psilocybin, and DMT (ayahuasca). The acute effects of these compounds are well-known as are their ability to increase the emotional state both in healthy people and in those with neuropsychiatric disorders. In particular psilocybin, the psychoactive...
Nature Reviews Drug Discovery June 1, 2022 Tristan D Mcclure-Begley, Bryan L. Roth 195 citations
Psychedelic drugs including psilocybin, N,N'-dimethyltryptamine (DMT) and lysergic acid diethylamide (LSD) are undergoing a renaissance as potentially useful drugs for various neuropsychiatric diseases, with a rapid onset of therapeutic activity. Notably, phase II trials have shown that psilocybin can produce statistically significant clinical effects following one or two administrations in...